Characteristics of Serotype 3 Invasive Pneumococcal Disease before and after Universal Childhood Immunization with PCV13 in Massachusetts

Impact of 13-valent pneumococcal conjugate vaccination on invasive pneumococcal disease in children under 15 years old in Madrid, Spain, 2007 to 2016: The HERACLES clinical surveillance study

(2019) Juan J. Picazo et al.   VACCINE

Streptococcus pneumoniae serotype 3 is masking PCV13-mediated herd immunity in Canadian adults hospitalized with community acquired pneumonia: A study from the Serious Outcomes Surveillance (SOS) Network of the Canadian immunization research Network (CIRN)

(2019) Jason J. LeBlanc et al.   VACCINE

Increase in Streptococcus pneumoniae serotype 3 associated parapneumonic pleural effusion/empyema after the introduction of PCV13 in Germany

(2019) D. Goettler et al.   VACCINE

Increase in incidence of invasive pneumococcal disease caused by serotype 3 in children eight years after the introduction of the pneumococcal conjugate vaccine in Hong Kong

(2018) Pak-Leung Ho et al.   Human Vaccines & Immunotherapeutics

Infants at risk for Invasive Pneumococcal Disease in the PCV13 Era

(2018) Inci Yildirim et al.   CLINICAL INFECTIOUS DISEASES

Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine Against Invasive Disease Caused by Serotype 3 in Children: A Systematic Review and Meta-Analysis of Observational Studies

(2018) Heather L Sings et al.   CLINICAL INFECTIOUS DISEASES

Immunization, Antibiotic Use, and Pneumococcal Colonization Over a 15-Year Period

(2017) Grace M. Lee et al.   PEDIATRICS

Impact of pneumococcal conjugate vaccine (PCV7 and PCV13) on pneumococcal invasive diseases in Italian children and insight into evolution of pneumococcal population structure

(2017) Romina Camilli et al.   VACCINE

Pneumococcal conjugate vaccine use in adults – Addressing an unmet medical need for non-bacteremic pneumococcal pneumonia

(2017) Heather L. Sings   VACCINE

Surveillance of pneumococcal colonization and invasive pneumococcal disease reveals shift in prevalent carriage serotypes in Massachusetts’ children to relatively low invasiveness

(2017) I. Yildirim et al.   VACCINE

Repeat pneumococcal polysaccharide vaccine in Indigenous Australian adults is associated with decreased immune responsiveness

(2017) Sarah Moberley et al.   VACCINE

The effect of pneumococcal conjugate vaccines on the incidence of invasive pneumococcal disease caused by ten non-vaccine serotypes in Denmark

(2016) Hans-Christian Slotved et al.   VACCINE

Vaccine effectiveness of PCV13 in a 3 + 1 vaccination schedule

(2016) Raphael Weinberger et al.   VACCINE

Effectiveness of 13-valent pneumococcal conjugate vaccine for prevention of invasive pneumococcal disease in children in the USA: a matched case-control study

(2016) Matthew R Moore et al.   Lancet Respiratory Medicine

Effectiveness of Pneumococcal Conjugate Vaccines (PCV7 and PCV13) against Invasive Pneumococcal Disease among Children under Two Years of Age in Germany

(2016) Mark van der Linden et al.   PLoS One

Capsular Polysaccharide (CPS) Release by Serotype 3 Pneumococcal Strains Reduces the Protective Effect of Anti-Type 3 CPS Antibodies

(2015) Eun Hwa Choi et al.   Clinical and Vaccine Immunology

Polysaccharide Conjugate Vaccine against Pneumococcal Pneumonia in Adults

(2015) Marc J.M. Bonten et al.   NEW ENGLAND JOURNAL OF MEDICINE

Invasive disease potential of pneumococci before and after the 13-valent pneumococcal conjugate vaccine implementation in children

(2015) Emmanuelle Varon et al.   VACCINE

A 13-year survey of pneumococcal nasopharyngeal carriage in children with acute otitis media following PCV7 and PCV13 implementation

(2015) Robert Cohen et al.   VACCINE

Pneumococcal serotype distribution in adults with invasive disease and in carrier children in Italy: Should we expect herd protection of adults through infants' vaccination?

(2015) Chiara Azzari et al.   Human Vaccines & Immunotherapeutics

Impact of 13-Valent Pneumococcal Conjugate Vaccination in Invasive Pneumococcal Disease Incidence and Mortality

(2014) Zitta Barrella Harboe et al.   CLINICAL INFECTIOUS DISEASES

Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study

(2014) Nick J Andrews et al.   LANCET INFECTIOUS DISEASES

Early impact of sequential introduction of 7-valent and 13-valent pneumococcal conjugate vaccine on IPD in Israeli children

(2014) Shalom Ben-Shimol et al.   VACCINE

Comparative Immunogenicity and Efficacy of 13-Valent and 7-Valent Pneumococcal Conjugate Vaccines in Reducing Nasopharyngeal Colonization: A Randomized Double-Blind Trial

(2013) Ron Dagan et al.   CLINICAL INFECTIOUS DISEASES

Pneumococcal vaccine and opsonic pneumococcal antibody

(2013) Joon Young Song et al.   JOURNAL OF INFECTION AND CHEMOTHERAPY

Estimating the Burden of Pneumococcal Pneumonia among Adults: A Systematic Review and Meta-Analysis of Diagnostic Techniques

(2013) Maria A. Said et al.   PLoS One

Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway

(2013) Anneke Steens et al.   VACCINE

Impact of 13-Valent Pneumococcal Conjugate Vaccination on Streptococcus pneumoniae Carriage in Young Children in Massachusetts

(2013) G. M. Lee et al.   Journal of the Pediatric Infectious Diseases Society

Hyporesponsiveness and its clinical implications after vaccination with polysaccharide or glycoconjugate vaccines

(2011) Jan Poolman et al.   Expert Review of Vaccines

Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine

(2011) Elizabeth Miller et al.   VACCINE

Association of Serotype with Risk of Death Due to Pneumococcal Pneumonia: A Meta‐Analysis

(2010) Daniel M. Weinberger et al.   CLINICAL INFECTIOUS DISEASES

Public health and economic impact of the 13-valent pneumococcal conjugate vaccine (PCV13) in the United States

(2010) Jaime L. Rubin et al.   VACCINE

A dynamic model of pneumococcal infection in the United States: Implications for prevention through vaccination

(2010) Thierry Van Effelterre et al.   VACCINE

Serotype specific invasive capacity and persistent reduction in invasive pneumococcal disease

(2010) Inci Yildirim et al.   VACCINE

Pneumococcal serotype 3 otitis media, limited effect of polysaccharide conjugate immunisation and strain characteristics

(2009) Jan Poolman et al.   VACCINE